Deal summary reprinted from Strategic Transactions - October 2009
Reconstructive device firm Biomet is acquiring fellow private company Cartilix (biomaterials) for an undisclosed amount. Read more...
Biomet buys biomaterials fim Cartilix
Deal summary reprinted from Strategic Transactions - October 2009
Five-year-old Cartilix has developed the ChonDux technology, which consists of a biological adhesive (chondroitin sulfate) and hydrogel (polyethylene glycol and hyaluronic acid) that photopolymerizes in situ to fill articular cartilage lesions. ChonDux is slated to begin clinical trials in Europe and the US next year. Biomet feels that Cartilix's technology will fit nicely with its own knee repair products, such as the MaxFire meniscal repair device and LactoNail for bone fixation.
Find out more about what our Strategic Transactions - The Device Deal Database can do for you.
Strategic Transactions - The Device Deal Database provides expanded information, including:
- Comprehensive Deal Records
- Complete Financial Information
- Extensive Company Profiles
- Access to important SEC Documents
- Links to related articles
Contact: James DeFalco at: +1 (203) 838-4401 x104 or [email protected].
Comments